News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Live Cell Imaging Market Outlook 2022”, live cell imaging is widely used for high content analysis and the adoption rate of high content screening is rising at a rapid pace. The technique is widely accepted by pharmaceutical and biotechnology companies for the validation and identification of potential toxicities and to elucidate a drug’s mechanism of action (MOA). Substantial efforts are being put by players to develop novel technology-based high content screening systems.

As the incidences of chronic diseases grow, so does the need for efficient drug therapies. The demand for high content screening is rising with the increasing need for development of new drug molecules with less potency. The technique is widely accepted by pharmaceutical and biotechnology companies for the validation and identification of potential toxicities and to elucidate a drug’s mechanism of action (MOA). Considerable efforts are being put by players to develop novel technology-based high content screening systems.
 
Several high content screening platforms are being developed by players of live cell imaging industry. For example, PerkinElmer, Inc. is offering Opera Phenix High Content Imaging System that features confocal solution for high content application. This system provides high throughput and phenotypic screening for complex disease models like live cells and microtissues. The developed markets such as the US and Europe are observing high adoption rate of cell screening procedures due to high technological awareness, increasing prevalence of metabolic and infectious diseases such as diabetes, HIV, Ebola and cancer, and increasing investments and funding by the North American and European governments.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM858.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm